<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Players</title>
	<atom:link href="http://www.tapanray.in/tag/players/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Covid Prompts Pharma To Move Away From Competition Driven Business Model</title>
		<link>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-prompts-pharma-to-move-away-from-competition-driven-business-model</link>
		<comments>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/#comments</comments>
		<pubDate>Mon, 26 Oct 2020 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dying]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-serving]]></category>
		<category><![CDATA[solo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10304</guid>
		<description><![CDATA[As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a &#8230; <a href="http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma To Leverage The Art of Turning Challenges Into Opportunities, Now</title>
		<link>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now</link>
		<comments>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/#comments</comments>
		<pubDate>Mon, 20 Jul 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[respelling]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[turning]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10179</guid>
		<description><![CDATA[Since, the dawn of the year 2020, the human population living in different countries, across the world are facing ‘lockdowns in different forms. Although essential, it severely restricts normal daily essential and other important activities of all. A large number &#8230; <a href="http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Sine Qua Non to Pharma Success in Digitized World</title>
		<link>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-sine-qua-non-to-pharma-success-in-digitized-world</link>
		<comments>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/#comments</comments>
		<pubDate>Mon, 16 Oct 2017 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalization]]></category>
		<category><![CDATA[Pharma. Success.Digitized. World]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sine Qua Non]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8472</guid>
		<description><![CDATA[A wind of change is now blowing at an accelerated speed &#8211; encompassing virtually anything, across the world, including India, with a varying degree, though. It leaves a profound impact on the day to day lives of many, including almost &#8230; <a href="http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In VUCA World: Changing Dynamics of Prescription Generation Process</title>
		<link>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-vuca-world-changing-dynamics-of-prescription-generation-process</link>
		<comments>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/#comments</comments>
		<pubDate>Mon, 04 Nov 2013 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AHJ]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[eluting]]></category>
		<category><![CDATA[empowerments]]></category>
		<category><![CDATA[frontline]]></category>
		<category><![CDATA[generating]]></category>
		<category><![CDATA[generation process]]></category>
		<category><![CDATA[Heart]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interaction]]></category>
		<category><![CDATA[interfaces]]></category>
		<category><![CDATA[intervention]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Mix]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[optimal]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[stent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[VUCA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4051</guid>
		<description><![CDATA[The acronym VUCA is often being used to emphasize upon the Volatility, Uncertainty, Complexity and Ambiguity in various situations. The term has been derived from military vocabulary and is being used since 1990s in the business management parlance. VUCA is also &#8230; <a href="http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-vuca-world-changing-dynamics-of-prescription-generation-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift</title>
		<link>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift</link>
		<comments>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/#comments</comments>
		<pubDate>Mon, 17 Jun 2013 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alibaba]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[composite]]></category>
		<category><![CDATA[Cosmetic]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[differentiated]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[Heralding]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[ICICI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Lombard]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mediclaim]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of pharma]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmacy-economics]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transition]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2454</guid>
		<description><![CDATA[In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various &#8230; <a href="http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India: Too Enticing a Pharma Market to Ignore by the Global Players despite unhappiness</title>
		<link>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness</link>
		<comments>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/#comments</comments>
		<pubDate>Mon, 22 Oct 2012 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[despite]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[Ignore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unhappiness]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1078</guid>
		<description><![CDATA[A White-Paper, titled “Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape”, released by a global technology and services company specializing in healthcare, Cegedim, in June, 2012 highlighted that 20 to 30 percent &#8230; <a href="http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India-like New Broader Compulsory Licensing Provisions in China Could Make the Global Pharma Players Edgy</title>
		<link>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy</link>
		<comments>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/#comments</comments>
		<pubDate>Mon, 18 Jun 2012 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Edgy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=79</guid>
		<description><![CDATA[Quite close on the heel of grant of Compulsory License (CL) to Bayer AG’s expensive Kidney and Liver cancer drug Sorafenib to the domestic Indian manufacturer Natco by the Indian Patent Office, as provided in the Indian Patent Law, China &#8230; <a href="http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantum Growth Envisaged in Government Procurement for Pharmaceuticals: A Challenging Ball Game for Pharma Players</title>
		<link>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players</link>
		<comments>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/#comments</comments>
		<pubDate>Mon, 27 Feb 2012 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[ball]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[Envisaged]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=128</guid>
		<description><![CDATA[Direct procurement by the Governments of various countries is attracting increasing importance not just at the domestic level, but internationally, as well. The systems adopted for Government Procurement (GP) globally are aimed at making a significant difference in the effectiveness &#8230; <a href="http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
